Le Lézard
Classified in: Health
Subject: LEG

Texas PBM Steerage Bill Becomes Law


AUSTIN, Texas, June 19, 2021 /PRNewswire-PRWeb/ -- In a significant victory for Texas pharmacists and their patients, Texas has enacted House Bill 1919, important legislation that protects community pharmacies and ensures patient choice by prohibiting pharmacy benefit managers (PBMs) from steering patients to pharmacies they own. The law will be effective September 1, 2021.

The Texas Pharmacy Association (TPA) identified PBM reform as a top priority for the 87th Legislative Session and worked closely with legislators to enact meaningful legislation. The three largest PBMs?which act as the middlemen between insurance companies, pharmacies and patients?control upwards of 80% of all prescription drug reimbursement in this country. While having a virtual monopoly on the payer side, they also own their own pharmacies that compete with local community pharmacies not affiliated with a PBM. Because PBMs are largely unregulated, they have been allowed to implement anti-competitive practices steering patients to their own pharmacies, which benefits their bottom line, limits patient choice, and harms small businesses.

"This legislation provides reasonable safeguards to ensure patients' best interests are protected, and that decisions based on profits do not overrule the choices of patients and their healthcare providers," said TPA President Michelle Beall, Pharm.D.

TPA is grateful to Texas legislators for recognizing that PBM practices shortchange pharmacists and create barriers, limiting access for patients to receive needed medications from their local pharmacy. PBM practices are rife with self-dealing and threaten community pharmacies' continued viability.

"What started in the 1980s as a mechanism to keep rising drug prices in check has turned into anti-free market steering practices that remove the patient from the decision-making process," said Representative Cody Harris, who authored the legislation. "House Bill 1919 brings competition to the marketplace and transparency to the consumer. With patient choice restored, this bill allows patients to once again choose their preferred pharmacy without being punished."

House Bill 1919 prohibits PBMs from steering patients to their affiliated pharmacies through online or patient-specific messaging. Additionally, it prohibits PBMs from requiring or inducing patients with reduced cost-sharing to use their affiliated pharmacy, prohibits PBMs from using patient-specific prescription information for commercial purposes, and requires patient consent to transfer a prescription.

This the second piece of PBM reform legislation enacted in Texas this year. In May, Governor Abbott signed into law House Bill 1763, which improves patient access to needed prescription drugs while ensuring pharmacies are protected from PBM overreach.

"We thank Governor Abbott for once again standing with Texas patients and acknowledging the need to reform this system," said TPA Chief Executive Officer Debbie Garza, R.Ph. "Community pharmacies have been under attack due to predatory business practices at the hands of PBMs. This legislation represents a significant step toward leveling the playing field for pharmacists across the state."

Media Contact

Debbie Garza, R.Ph., Texas Pharmacy Association, +1 512-615-9140, [email protected]

Twitter

SOURCE Texas Pharmacy Association


These press releases may also interest you

at 00:05
As May marks Preeclampsia Awareness Month, leading maternal health experts, preeclampsia survivors and industry leaders have come together on a new campaign, "Preeclampsia Prevention is Possible." The campaign elevates awareness of a major paradigm...

30 avr 2024
The report titled "Clinical Trial Analytics Services Market by Services (Clinical Data Analytics, Clinical Trial Data Management, Clinical Trial Planning & Monitoring), Component (Data Management & Integrity Services, Data Visualization &...

30 avr 2024
Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online. Prof. Yuankai Shi, chief physician of...

30 avr 2024
Waverley Pharma Inc. ("Waverley Pharma" or the "Company") , a Canadian pharmaceutical company, is announcing a business update. As mentioned in the previous business update dated August 2, 2023, opportunities Waverley Pharma envisioned of marketing...

30 avr 2024
Feeding Matters is proud to celebrate the 6th annual PFD Awareness Month, which is recognized around the globe. This designation, initiated by Feeding...

30 avr 2024
Korea Ginseng Corp. US (KGCUS) aka JungKwanJang held a dedicated international seminar session on "Korean Ginseng: Safety, Efficacy And Neuroprotective Insights'' at the International Conference on the Science of Botanicals (ICSB) hosted by the...



News published on and distributed by: